Vera Therapeutics, Inc.
VERA
$21.71
-$0.32-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.00M | 41.00M | 31.67M | 27.84M | 25.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.25M | 167.17M | 145.28M | 117.24M | 101.87M |
| Operating Income | -193.25M | -167.17M | -145.28M | -117.24M | -101.87M |
| Income Before Tax | -175.46M | -152.15M | -134.38M | -107.85M | -94.30M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -175.46 | -152.15 | -134.38 | -107.85 | -94.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.46M | -152.15M | -134.38M | -107.85M | -94.30M |
| EBIT | -193.25M | -167.17M | -145.28M | -117.24M | -101.87M |
| EBITDA | -191.59M | -165.59M | -143.75M | -115.72M | -101.33M |
| EPS Basic | -2.99 | -2.74 | -2.60 | -2.20 | -2.04 |
| Normalized Basic EPS | -1.87 | -1.71 | -1.62 | -1.38 | -1.28 |
| EPS Diluted | -2.99 | -2.74 | -2.60 | -2.20 | -2.04 |
| Normalized Diluted EPS | -1.87 | -1.71 | -1.62 | -1.38 | -1.28 |
| Average Basic Shares Outstanding | 233.99M | 221.29M | 205.05M | 194.52M | 184.06M |
| Average Diluted Shares Outstanding | 233.99M | 221.29M | 205.05M | 194.52M | 184.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |